SUMMARY Sulphasalazine (salicyl-azo-sulphapyridine) was ingested by 27 healthy subjects for five days at a dosage of 4 g daily. The acetylator phenotype of each subject had been established previously. The serum concentrations of the parent drug and its sulphapyridine-metabolites were determined and the adverse effects were recorded. There was no correlation between the serum concentrations of sulphasalazine and the adverse effects. The slow acetylators obtained enhancement of serum concentrations of sulphapyridine earlier than the rapid acetylators. They also reported adverse effects earlier and of more pronounced nature than the rapid acetylators. The data as a whole suggest that the adverse effects observed were caused by the metabolite sulphapyridine and that they are influenced by the polymorphic acetylation.
salicylic acid (Svartz, Kallner, and Helander, 1945) . This process probably occurs in the large intestine. A considerable proportion of sulphapyridine (as well as unsplit sulphasalazine) is absorbed whilst the 5-amino salicylic acid moiety is largely excreted in faeces (Schroder and Campbell, 1972) . Sulphapyridine, like sulphadimidine, isoniazid, and other drugs, is polymorphically acetylated in man (Schroder and Evans, 1972) , some persons being genetically constituted as rapid acetylators (Mendelian dominants) and others as slow acetylators (recessives). Sulphapyridine is metabolized by both acetylation and hydroxylation. The products of the latter process appear in blood and urine conjugated to glucuronic acid. The current concept of the pharmacokinetics of sulphasalazine in man is summarized in Figure 1 .
The aims of the present study were to see if the adverse effects of sulphasalazine were correlated with the serum concentrations of the parent drug or its metabolites or influenced by the polymorphic acetylation of sulphapyridine.
Methods
Twenty-seven healthy subjects (university medical school laboratory technicians, physicians, nurses, and final-year medical students) without a history of asthma, hay fever, eczema, adverse reactions to any drug, or gastrointestinal disorders participated in the experiment. Twelve of the subjects were female. The subjects were motivated to participate in the research in the sense that most had previously taken part in other experiments on drug metabolism and so were interested in the topic. With the exception of two slow acetylators, the subjects were not aware of their acetylator phenotypes. All volunteer subjects were paid and the sum paid was the same whether or not they completed the full 120 hours of the study. The first four subjects did not know about the adverse effects until they had actually experienced symptoms. Since most of the subjects worked in the same building and were able to discuss and compare their symptoms, it then became generally known that adverse effects occurred during this experiment.
The subjects were phenotyped as slow (15 subjects) or rapid (12 subjects) acetylators of sulphadimidine and sulphapyridine according to the procedure given by Evans (1969 (Dixon, 1965) .
Results

PHARMACOKINETICS
There was a pronounced interindividual variation in serum concentrations of sulphasalazine (Fig. 2a) (Table I) .
The acetylator phenotype had a significant influence upon the serum concentrations in that the slow acetylators had more of sulphapyridine and less of acetyl sulphapyridine and acetyl sulphapyridine-0-glucuronide than the rapid acetylators (Fig. 2c-e and Table I ). The slow acetylators had a significantly lower percentage of glucuronidized sulphapyridine in serum than the rapid acetylators (Table I) . No difference between sexes in serum concentrations of any metabolite was found. The slow and rapid acetylators did not differ significantly from each other in their mean age, body weight, or height.
Urine was obtained from 16 subjects (seven slow and nine rapid acetylators). The total urinary excretions of sulphasalazine and its sulphapyridine metabolites were lower in the slow than in the rapid acetylators but the difference failed to attain statistical significance (Table LI acetylators excreted a higher proportion as sulphapyridine and sulphapyridine-O-glucuronide and a lower proportion as each of the two acetylated metabolites than the rapid acetylators. These differences between slow and rapid acetylators were significant (Table II) . However, the proportion in urine of sulphasalazine and of sulphapyridine that was glucuronidized was not significantly different for the two acetylator phenotypes (Table II) .
ADVERSE EFFECTS
Of the 15 slow and 12 rapid acetylators participating in the study, 14 slow and 10 rapid acetylators reported at least one adverse effect and 10 slow and seven rapid acetylators (in all 63%) discontinued taking the tablets before the end of the experiment because of the severity of the symptoms. Figure 3 shows that of the slow acetylators, one discontinued after day 1, five after day 2, and two after each of days 3 and 4. Of the rapid acetylators, three discontinued the experiment after day 3 and four after day 4. Neither of the sexes was represented more significantly among those who discontinued before the end of the study (tested by x2 with Yates' correction). Serum concentrations of sulphasalazine, sulphapyridine, and metabolites after 24 hours' therapy in subjects who discontinued before 72 hours were compared (separately in the two acetylator phenotypes) with 24-hour values in subjects who continued the experiment to give blood specimens after 72 hours. No significant differences were found. Similarly, no significant differences in serum concentrations were found after 72 hours between subjects who discontinued before 120 hours and those who completed the study (Fig. 2a-e) . Neither of the acetylator phenotypes was significantly more represented among those who discontinued before the end of the study (tested by x2 with Yates' correction).
Among those who discontinued before the end of the study, the slow acetylators consumed 22X2 ± 5.6 tablets (mean ± 95% confidence limits assuming by 27 healthy subjects (15 slow and 12 rapid acetylators ofsulphapyridine) for as long as they ingested 4 g sulphasalazine daily for five days. t distribution) and the rapid acetylators 30.9 ± 4.5 tablets (mean ± 95% confidence limits assuming t distribution). This difference between slow and rapid acetylators is significant (p = 0.02).
During the investigation, 14 different adverse symptoms were recorded. Figure 4 gives their nature and incidence for slow and rapid acetylators. Most frequent were nausea, headache, and abdominal discomfort. The slow acetylators had a higher incidence than the rapid acetylators of 11 of the symptoms and the same incidence of two symptoms. Five (33%) of the slow acetylators vomited and the same number of them had diarrhoea but none of the rapid acetylators reported any of these symptoms. The number of adverse effects reported by each subject was higher for the slow acetylators than for the rapid acetylators (Table III) , and when considering only those who discontinued before the end of the study, the difference between the acetylator phenotypes was significant, P = 0035 (Table III) . There was a distinct impression that the adverse effects were worse when physical exertion was greater. The one subject who reported pain in the lumbar area had a very low intake of liquids.
Discussion
Our results show that the adverse effects experienced by subjects ingesting sulphasalazine were correlated with the acetylator phenotype in that slow acetylators of sulphapyridine developed a greaternumber of symptoms which appeared earlier than in the rapid acetylators.
In this study nausea, headache, and abdominal discomfort were the most frequent symptoms reported by the subjects and they are common symptoms registered for patients on sulphasalazine therapy (Svartz, 1942; Lagercrantz, 1949; Morrison, 1952; Moertel and Bargen, 1959; Lennard-Jones et al, 1960; Watkinson, 1961; Baron et al, 1962; Truelove et al, 1962; Dick et al, 1964; Misiewicz et al, 1965; Collins, 1968) . Nausea and headache are common symptoms also for patients on sulphapyridine therapy (Hawking and Lawrence, 1950) .
About 63% of the subjects stopped the experiment because of side effects and this high incidence is a relatively undesirable aspect of the study.
The higher incidence of adverse effects found by us compared with experiences in the therapeutic use of sulphasalazine may be due to a combination of factors. It is well known that subjects on treatment even with placebo will report subjective adverse effects. Since in this study many subjects had some forewarning of the possible occurrence of adverse effects, perhaps 'placebo effects' may have been magnified. The fact that most of the subjects worked in the same building allowed the subjects to compare their impressions of the pharmacokinetic study in which they were participating. If a colleague suffered from severe adverse effects, a subject might overestimate his own pain and thus stop participating in the study. There is, however, no reason to suppose that the two acetylator phenotypes differ in their reactions to placebo or to gossip in the surroundings. The participants were healthy subjects performing their normal work in the laboratories and in the ward. Any impairment of their ability to perform normal duties would be recognized and decrease their desire to continue the experiment. Patients suffering from ulcerative colitis are, however, very willing to withstand some degree of adverse effects without complaint because of the prospect of benefit from sulphasalazine therapy. There may be differences in the metabolism of sulphasalazine between healthy subjects and patients suffering from ulcerative colitis. The portion of sulphasalazine that is not absorbed along the small intestine enters the large intestine. We expect a patient suffering from ulcerative colitis to excrete this sulphasalazine in the stools before sulphapyridine is formed and absorbed, especially during the acute stage of the disease. This should give patients a slower increase in serum concentration of sulphapyridine than healthy subjects and they may thus more easily get accustomed to the drug. The impression that the adverse effects were worse when physical exertion was greater suggests that healthy subjects can have more severe symptoms than ulcerative colitis patients because they are more ambulant. During the studies reported by Evans (1969) many complaints of headaches and malaise were encountered in healthy working volunteers on high doses of sulphadimidine, but these were almost completely eliminated either by insisting on complete recumbency during the first two hours of the test or by reducing the dose. It must be emphasized that the metabolism of sulphasalazine may be different in normals and subjects with ulcerative colitis because of the disease processes. The conclusions reached in this study on normal subjects cannot, therefore, necessarily be applied to patients for whom the drug is used therapeutically.
There are no significant indications that higher serum concentrations of sulphasalazine increases the severity of the adverse effects. The present data as a whole indicate that the adverse effects that occur in subjects on sulphasalazine may be caused mainly by sulphapyridine and that the slow acetylators of sulphapyridine develop more symptoms which appear earlier than in rapid acetylators. Such a view would be in keeping with two previously published observations, viz, (1) that slow acetylators have a higher incidence of polyneuropathy on isoniazid treatment than rapid acetylators (Devadatta, Gangadharam, Andrews, Fox, Ramakrishnan, Selkon, and Velu, 1960) , and (2) that in a double-blind investigation on phenelzine, Evans, Davison, and Pratt (1965) found that the severe adverse effects occurred only in slow acetylators. We gratefully acknowledge the help of Miss M. F. Bullen and of Miss Lena Carlsson-
